Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Last Updated: 2026

Day One Biopharmaceuticals

Rank#4754

Market Cap2.22B

CountryUnited States

Summary

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

History

Day One Biopharmaceuticals was founded in 2016 with the ambition to make meaningful improvements in the lives of patients living with rare diseases. We focus on the development and commercialization of innovative therapies targeting unmet medical needs in rare diseases.

Mission

Our mission is to innovate and develop therapies that have the potential to profoundly improve the lives of patients living with rare diseases such as lysosomal storage disorders, mitochondrial diseases, neurometabolic diseases and other rare genetic diseases.

Vision

We envision a world in which our therapies make a visible, life-changing difference in the health and wellbeing of patients and families living with rare diseases.

References

https://www.investing.com/equities/dot-therapeutics2

https://finance.yahoo.com/quote/DAWN/profile?p=DAWN

https://www.crunchbase.com/organization/day-one-biopharmaceuticals

https://sec.report/CIK/0001845337

https://companiesmarketcap.com/

https://dayonebio.com

Leadership team

Dr. Jeremy Bender M.B.A., Ph.D. (CEO, Pres & Director)

Dr. Samuel C. Blackman M.D., Ph.D. (Co-Founder & Chief Medical Officer)

Ms. Julie Papanek Grant M.B.A. (Co-Founder & Director)

Products / Services

Biopharma, Biotechnology, Health Care, Pharmaceutical

Number of Employees

50 - 100

Address

South San Francisco, California, United States

Established

2018-01-01

Company Registration

SEC CIK number: 0001845337

Traded as

DAWN

Website

https://dayonebio.com

Social Media

Last Updated: 2026

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More

Last Updated: 2026

Day One Biopharmaceuticals

Rank#4754

Market Cap2.22B

CountryUnited States

Summary

History

Mission

Vision

We envision a world in which our therapies make a visible, life-changing difference in the health and wellbeing of patients and families living with rare diseases.

References

https://www.investing.com/equities/dot-therapeutics2

https://finance.yahoo.com/quote/DAWN/profile?p=DAWN

https://www.crunchbase.com/organization/day-one-biopharmaceuticals

https://sec.report/CIK/0001845337

https://companiesmarketcap.com/

https://dayonebio.com

Leadership team

Dr. Jeremy Bender M.B.A., Ph.D. (CEO, Pres & Director)

Dr. Samuel C. Blackman M.D., Ph.D. (Co-Founder & Chief Medical Officer)

Ms. Julie Papanek Grant M.B.A. (Co-Founder & Director)

Products / Services